Scarica l'app Stockscreener
72.47
0.47%
0.34
Dopo l'orario di chiusura:
72.53
0.06
+0.08%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HALO Giù?
Forum
Previsione
Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie
Is Halozyme Therapeutics Inc. (RV7) stock undervalued after correction2025 Dividend Review & Breakout Confirmation Alerts - ulpravda.ru
How Halozyme’s ENHANZE–Vedolizumab Deal With Takeda At Halozyme Therapeutics (HALO) Has Changed Its Investment Story - Yahoo Finance
Is Halozyme Therapeutics (HALO) Pricing Reflect Its DCF And P/E Signals After Recent Gains - Yahoo Finance
Halozyme, Takeda in arrangement to use former's drug delivery tech in Entyvio - MSN
How supply chain issues affect Halozyme Therapeutics Inc. stockPortfolio Risk Report & Consistent Profit Alerts - ulpravda.ru
Will Halozyme Therapeutics Inc. stock see insider buyingDividend Hike & Verified Technical Signals - ulpravda.ru
Is Halozyme Therapeutics Inc. stock ready for breakout2025 Key Highlights & Growth Focused Entry Reports - ulpravda.ru
Can Halozyme Therapeutics Inc. stock surprise with earnings upsideQuarterly Profit Review & Daily Momentum Trading Reports - ulpravda.ru
TD Cowen Raises Price Target for HALO to $90.00, Maintains Buy Rating | HALO Stock News - GuruFocus
TD Cowen raises Halozyme Therapeutics stock price target to $90 on growth outlook - Investing.com Canada
Halozyme Partners with Takeda to Develop and Commercialize Vedolizumab - Contract Pharma
Halozyme Allows Takeda To Access Its ENHANZE Drug Delivery Technology For Use With Vedolizumab - Nasdaq
Takeda (TAK) Partners with Halozyme for Enhanced Drug Delivery - GuruFocus
Halozyme signs licensing deal with Takeda for vedolizumab delivery tech By Investing.com - Investing.com Australia
Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE - Chartmill
Why Halozyme Therapeutics Inc. stock remains undervaluedLarge Cap Stability Picks & Low Cost Capital Trading - ulpravda.ru
Is It Too Late To Consider Halozyme Therapeutics (HALO) After A 43% One-Year Surge? - Sahm
A Look At Halozyme Therapeutics (HALO) Valuation After New ENHANZE Obesity Partnership With Skye Bioscience - Yahoo Finance
Halozyme Therapeutics (HALO): Buy, Sell, or Hold Post Q3 Earnings? - Finviz
Insider Sell: Bernadette Connaughton Sells 2,000 Shares of Haloz - GuruFocus
Halozyme and Skye partner on obesity drug delivery technology By Investing.com - Investing.com Nigeria
Skye Bioscience shares rise on Halozyme partnership to advance obesity treatment - MSN
Halozyme Therapeutics, Skye Bioscience Collaborate to Evaluate Nimacimab for Obesity Treatment - MarketScreener
Skye Bioscience Licenses Halozyme’s ENHANZE Drug Delivery Technology - Contract Pharma
Skye Bioscience stock jumps after Halozyme collaboration for obesity drug By Investing.com - Investing.com Nigeria
Skye Bioscience stock jumps after Halozyme collaboration for obesity drug - Investing.com
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Robust Revenue Growth and Strategic Partnerships Fuel Investor Optimism - DirectorsTalk Interviews
Halozyme Therapeutics (HALO) Partners with Skye Bioscience for I - GuruFocus
Halozyme (HALO) Partners with Skye Bioscience for Obesity Treatm - GuruFocus
Halozyme and Skye partner on obesity drug delivery technology - Investing.com
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity - The Manila Times
Biotechs team up to test higher-dose obesity shots in mid-2026 trial - Stock Titan
Halozyme Therapeutics (FRA:RV7) EV-to-OCF : 14.00 (As of Jan. 04, 2026) - GuruFocus
Cwm LLC Acquires 22,813 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Arbor Investment Advisors LLC Invests $1.32 Million in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Valuation Update: Why Halozyme Therapeutics Inc RV7 stock is a must watch tickerJuly 2025 Rallies & Low Drawdown Trading Techniques - moha.gov.vn
Halozyme Therapeutics (NASDAQ:HALO) Reports Bullish Q3 CY2025 - The Globe and Mail
How Halozyme Therapeutics Inc. (HALO) Affects Rotational Strategy Timing - Stock Traders Daily
Here's What Analysts Think About Halozyme Therapeutics (HALO) - Finviz
Here’s What Analysts Think About Halozyme Therapeutics (HALO) - Insider Monkey
Market Still Lacking Some Conviction On Halozyme Therapeutics, Inc. (NASDAQ:HALO) - 富途牛牛
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Rating of "Hold" by Brokerages - MarketBeat
Zacks Research Brokers Increase Earnings Estimates for HALO - MarketBeat
Shaker Investments LLC OH Decreases Stock Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Voya Investment Management LLC Has $3.39 Million Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Pacer Advisors Inc. Acquires 456,649 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Osaic Holdings Inc. Grows Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Hedge Fund and Insider Trading News: Steve Cohen, Ray Dalio, Warren Buffett, Alan Howard, Scott Bessent, Saba Capital Management, Halozyme Therapeutics Inc (HALO), Epsilon Energy Ltd (EPSN), and More - Insider Monkey
Halozyme Therapeutics CEO sells $1.14 million in stock - Investing.com
Halozyme Therapeutics Stock Sees Relative Strength Rating - Investor's Business Daily
27,468 Shares in Halozyme Therapeutics, Inc. $HALO Acquired by Monument Capital Management - MarketBeat
Halozyme Therapeutics (HALO): Valuation Check After FDA Win and Patent Court Victory - Yahoo Finance
Halozyme Therapeutics (HALO) Is Up 7.4% After New ENHANZE NSCLC Win And Patent InjunctionWhat's Changed - Yahoo Finance
Is Halozyme Still Attractively Priced After Its Strong 2025 Share Price Rally? - Yahoo Finance
EBITDA per share of Halozyme Therapeutics, Inc. – TRADEGATE:RV7 - TradingView — Track All Markets
Halozyme Therapeutics (BIT:1HALO) Price Target Decreased by 13.37% to 59.51 - Nasdaq
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):